Editorial standards

Editorial standards

Our Editorial Principles

Our patient portal "Janssen With Me" is aimed at patients and their families with information on the latest developments in medicine, diseases and our offers and support options. Our offer includes:

  • Information for everyday life for patients and interested parties
  • Services and comprehensible information about diseases, forms of support options
  • Current and reputable information and materials for download about:
    • autoimmune diseases
    • rare diseases
    • cancer diseases
    • infectious diseases
    • Lung diseases
    • mental diseases
    • neurological diseases
  • Networking with patient organizations and self-help groups

In the editorial articles and publications publicly available on our platform, the focus is on scientific information.

This policy document aims to clearly summarize the editorial principles and make them available to the public

The target group for our offer

The contents of our digital portal are aimed at those affected by and interested in the following therapeutic areas:

  • Oncology (Hemato-Oncology, Uro-Oncology)
  • Pulmonology (pulmonary hypertension)
  • Neuroscience (psychiatry and neurology)
  • Immunology (Gastroenterology, Dermatology and Rheumatology)
  • Internal medicine
  • Infectiology

Our Credo: Responsibility

At Janssen, we are committed to providing the most up-to-date information on our therapeutic areas and clinical research and development activities, as well as helping readers and users to manage their daily lives with the disease.

We therefore provide content on our patient portal that is based on trustworthy sources, such as renowned medical journals, and reflects the current state of research. The content is also researched and developed together with patients to meet their needs.

Our approach at Janssen is holistic, combining economic, ecological and social dimensions. This is based on the Credo of responsibility established by our parent company Johnson & Johnson as early as 1943. For 80 years, we have been committed to meeting the concerns of our patients, as well as those of our employees, pharmacists and physicians.

At the same time, we base our business activities on the principle of sustainability, place particular emphasis on research conducted in accordance with ethical standards, and are committed to social projects and to improving health in developing and emerging countries.

In addition to our interest in medical progress in line with the highest ethical standards in research, we at Janssen have established patient safety as the cornerstone of our actions.

Given our holistic view of patient care in the EMEA region, our primary concern with this portal is to provide only carefully selected information.

Patient orientation

The aim of our portal is to provide a broad spectrum of information that helps in understanding diseases, to make therapy approaches comprehensible and also to support family members. Readers and users should be enabled to make well-informed decisions.

To this end, we evaluate various sources for the individual medical topics.

Our topic-specific content is based on our holistic approach: we offer information on studies, what treatment options are available, and even materials for targeted contacts with other support options, such as patient organizations and self-help organizations.

Quality Assurance and Transparency

The content of our portal is created and reviewed by an interdisciplinary team of internal and external authors and experts in their respective fields. The editing of the content goes through a multi-stage process.

All content such as text, graphics, photos and videos are carefully selected, created and referenced (e.g. scientific studies and publications such as peer-reviewed articles in recognized journals). Before the content is published on our portal, it undergoes an approval process to ensure, among other things, that the data is up-to-date and professionally correct.

Communication experts are also involved in internal quality assurance. They ensure that the texts are written in a comprehensible and easily readable manner.

Transparency of funding and advertising

At Janssen, we are committed to transparency and disclosure.

"Janssen With Me" is editorially independent. There is no third-party advertising content or editorial commentary, nor are there any external sponsorships on our pages. The digital platform is financed entirely by Janssen Pharmaceutica NV and our parent company Johnson & Johnson.

If reference is made on the platform to other service providers, external sources, or other internet sites, these external references are clearly marked as such.

If physicians and other medical professionals involved in the creation of the content have relevant connections to commercial structures, we will also identify these.

Beyond the usual transparency, the pharmaceutical industry has committed itself to disclosing financial benefits within the framework of the Transparency Code. The publication of payments and monetary benefits to physicians and medical organizations has been freely accessible since the introduction of the disclosure requirement on January 1, 2015. Benefits to patient organizations have already been published in a freely accessible form since 2008.

In order to create transparency, we follow the EFPIA (European Federation of Pharmaceutical Industries and Associations) Code.

This enables us to work transparently with other players in the healthcare sector.

Further details on our disclosure methodology can be found on our page: "Disclosure: Janssen follows this methodology".

Data protection

The protection of the privacy of users of the Janssen With Me portal is a high priority for us. We respect the protection of your data on the internet and want to ensure the highest level of security and transparency when dealing with your personal information.

Therefore, it is important for us, as the operator of the internet portal, to comply with the requirements of data protection. We always collect and process personal data in compliance with European data protection laws and our company's privacy policy.


Kostopoulos, Ioannis V., et al. "Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches." Frontiers in Oncology 10. 2020; 860.
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson